glp 1 oral fda approved Semaglutide Gets Approval for CV Event Reduction in High-risk Diabetes Patients Weight Loss Blog – Maryland

Adoption remained modest until recent years as GLP-1 drug claims rose from 6.9 percent in 2023 to 10.5 percent in 2025

If you do not have metabolic disease, the idea of using GLP-1 purely for dementia prevention is more speculative

Contamination at this stage introduces bacteria that can multiply in the solution over the coming weeks, ruining the entire vial

There was a statistically significant reduction in the primary endpoint, which was a composite of cardiovascular death or worsening HF events, with an RRR of 33%

Is Retatrutide Safe

Between December 2025 and January 2026, both of these MDLs gained new plaintiffs